Anirban Maitra, Scientific Director of Sheikh Ahmed Center for Pancreatic Cancer Research and Professor of Pathology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center, shared a post on X:
“A comparison of emerging data of first line KRAS inhibition combined with chemotherapy (G plus A) in advanced Pancreatic Cancer.
Left: KRAS G12D allele specific Inh HRS-4642 to be presented at ESMO25
Right: RevMed multiRAS inh Daraxonrasib
Toe-to-Toe…”
More posts featuring Anirban Maitra.